Client Description: Clinical-stage biotech advancing antibody complement therapeutics for autoimmune diseases. The company was preparing for a reverse merger and aimed to position itself as a leader in its field, leveraging preclinical and clinical data to attract investor interest.
Objectives: Develop and execute IR and corporate affairs strategies to communicate the company’s scientific vision and performance to stakeholders. Create a roadmap for pre- and post-IPO communications, establish strong relationships with analysts and investors, and ensure the market understands the company’s potential as it goes public.
Key Metrics:
- Days to first candidate presented: 3
- Candidates submitted: 14
- Days until offer accepted: 109